The US FDA reorganises its review functions
This article was originally published in Scrip
Executive Summary
The US FDA has realigned various review functions of its six Offices of Drug Evaluation (ODE) within the Center for Drug Evaluation and Research's Office of New Drugs in order to enhance the logical groupings of applications.